Identifying key genes in liver cancer for better treatment
A Single-center Study of the Identification and Prognostic Value of Key Genes in Hepatocellular Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University · NCT05759858
This study is trying to find important genes in liver cancer to help develop new treatments and improve early detection for people with the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Trial ID | NCT05759858 on ClinicalTrials.gov |
What this trial studies
This study aims to explore the key genes associated with hepatocellular carcinoma (HCC) in both human and mouse models. By utilizing high-throughput sequencing technology, researchers will identify prognostic markers and key genes that could lead to the development of small molecule drugs targeting these genes. The study addresses the urgent need for new biomarkers to improve the early detection and prognosis of liver cancer, which is often diagnosed at advanced stages due to a lack of early symptoms. The research will analyze gene expression levels to differentiate between cancerous and non-cancerous liver tissues.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with pathologically confirmed hepatocellular carcinoma who have no significant comorbidities and have completed surgery.
Not a fit: Patients with a history of other tumors, multiple lesions, or significant organ diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved early detection and targeted therapies for patients with hepatocellular carcinoma.
How similar studies have performed: Other studies have shown promise in identifying genetic markers for liver cancer, but this approach may offer novel insights into targeted therapies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Hepatocellular carcinoma confirmed by pathology; 2. The patient has no combined organic diseases of heart, lung, and kidney, etc; 3. No history of chemotherapy, radiotherapy, upper abdominal surgery, or combined with other tumors; 4. The patient has successfully completed the operation and has complete clinical information and pathological data. Exclusion Criteria: 1. Patients who have previous history of other tumors or have undergone upper abdominal surgery; 2. Patients with multiple lesions and distant metastasis; 3. Patients who are complicated with organic diseases of important organs such as heart, lung and kidney and cannot tolerate surgery； 4. Patients who are more than 75 years old or less than 18 years old.
Where this trial is running
Hangzhou, Zhejiang
- 2nd Affiliated Hospital, School of Medicine, Zhejiang University — Hangzhou, Zhejiang, China (RECRUITING)
Study contacts
- Principal investigator: Yuancong Jiang, Doctor — 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
- Study coordinator: Sheng Yan, Doctor
- Email: shengyan@zju.edu.cn
- Phone: 13957161680
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Hepatocellular Carcinoma, Hepatocellular carcinoma, Genomes, Prognosis, Gene targeted therapy